GBS: When Your Immune System Becomes Your Worst Enemy
By Arunima Rajan
In an interview with Arunima Rajan, Dr. Annu Aggarwal, consultant, neurology, Kokilaben Dhirubhai Ambani Hospital, Mumbai says that the exact reason why only a small percentage of people develop GBS after infections is not fully understood, but it likely involves a combination of genetic, immunological, and environmental factors.
Guillain-Barré Syndrome (GBS) feels like a disorder shrouded in mystery. Could you walk me through how the disease takes hold in the human body, perhaps unpacking it in layman’s terms?
Guillain-Barré Syndrome (GBS) is an autoimmune disorder where the immune system, which is normally designed to protect the body from infections, malfunctions and begins attacking the peripheral nerves. These nerves are responsible for transmitting signals between the brain and the rest of the body, enabling movement, sensation, and coordination. In GBS, the immune system targets the myelin sheath, which is the protective covering of the nerves, or the nerve axons themselves, leading to inflammation and damage. The process often starts after an infection, such as a respiratory or gastrointestinal infection, where the immune system generates antibodies to fight off the pathogen. However, due to a phenomenon called molecular mimicry, these antibodies mistakenly attack the body’s own nerve cells because they resemble the proteins of the invading pathogen. This cross-reaction leads to inflammation and damage to the nerves, disrupting their ability to transmit signals. As a result, the brain’s commands cannot reach the muscles effectively, leading to symptoms like muscle weakness, numbness, and in severe cases, paralysis. The weakness typically starts in the legs and ascends to the arms and upper body. In some cases, it can affect the muscles responsible for breathing and swallowing, requiring urgent medical intervention. The immune system’s attack on the nerves is like a case of mistaken identity, where the body’s defence mechanism turns against itself, causing widespread damage to the nervous system. The progression of GBS can be rapid, with symptoms worsening over days or weeks, and the severity can vary from mild weakness to complete paralysis. The exact trigger for this autoimmune response is not fully understood, but it is believed to involve a combination of genetic predisposition, environmental factors, and the specific immune response to an infection. Recent research suggests that certain gut microbiota alterations may also play a role in predisposing individuals to GBS, highlighting the need for further exploration into gut-immune interactions in autoimmune neuropathies.
I’m intrigued by this concept of ‘molecular mimicry’—the idea that your body gets tricked into attacking itself. Could you elaborate a bit on how this process might play out specifically in GBS?
Molecular mimicry is a fascinating yet devastating phenomenon where the immune system mistakes the body’s own tissues for foreign invaders, such as bacteria or viruses. In GBS, this usually happens after an infection. For example, when someone is infected with a virus or bacteria, the immune system generates antibodies to fight off the pathogen. However, due to structural similarities between the pathogen and the body’s own nerve cells, these antibodies may also attack the nerves. This cross-reaction leads to inflammation and damage to the myelin sheath or the nerve axons. The immune system’s attack on the nerves disrupts their ability to transmit signals, causing the symptoms of GBS. This process is not fully understood, but it is believed to be a key mechanism in the development of the disease. The immune system, which is supposed to protect the body, ends up causing harm because it cannot distinguish between the foreign invader and the body’s own tissues. This is why GBS is often described as a case of the immune system going rogue. The antibodies generated to fight the infection end up attacking the nerves, leading to the characteristic symptoms of GBS. The damage to the nerves can be severe, and the recovery process depends on how quickly the immune system’s attack is halted and how much damage has already been done. Emerging evidence has shown that infections caused by Campylobacter jejuni, particularly strains containing the sialylated lipooligosaccharide structure, have a high likelihood of triggering GBS via molecular mimicry, which is why this bacterium is one of the most well-recognised causative agents of the syndrome. The concept of molecular mimicry highlights the complexity of the immune system and how a well-intentioned defence mechanism can sometimes go awry, leading to autoimmune diseases like GBS.
Dr. Annu Aggarwal
GBS seems to flare up after certain infections like COVID-19 or Zika. But infections are common; GBS isn’t. Why do some bodies react so dramatically, while others remain unaffected?
The exact reason why only a small percentage of people develop GBS after infections is not fully understood, but it likely involves a combination of genetic, immunological, and environmental factors. Some individuals may have a genetic predisposition that makes their immune system more likely to misfire and attack their own nerves. Additionally, the specific type of infection and the immune response it triggers may play a role. For example, certain viruses or bacteria may have components that closely resemble nerve cells, increasing the risk of molecular mimicry. Environmental factors, such as overall health, stress, or previous immune challenges, may also influence the likelihood of developing GBS. Most people’s immune systems can distinguish between foreign invaders and the body’s own tissues, but in rare cases, this mechanism fails, leading to autoimmune reactions like GBS. The immune system’s ability to recognise and tolerate the body’s own tissues is a finely tuned process, and when this balance is disrupted, it can lead to autoimmune diseases. In the case of GBS, the immune system’s response to an infection goes awry, leading to an attack on the nerves. This is why GBS is relatively rare, even though infections are common. The rarity of GBS is a testament to the efficiency of the immune system in most people, but it also highlights the complexity of autoimmune diseases and the challenges in understanding why they occur in some individuals and not others. The interplay between genetics, the immune system, and environmental triggers makes GBS a complex and unpredictable condition. There is also increasing interest in the role of host genetic variations, particularly in immune-related genes such as human leukocyte antigen (HLA) alleles, which might determine an individual’s susceptibility to post-infectious autoimmunity like GBS.
One variant, Acute Motor Axonal Neuropathy (AMAN), sounds particularly severe and is reportedly more common in China. Are there genetic or environmental reasons for regional variations in the prevalence or severity of GBS?
Regional variations in GBS subtypes, such as Acute Motor Axonal Neuropathy (AMAN), may be influenced by a combination of genetic and environmental factors. In China, AMAN is more commonly reported, and this could be due to genetic differences in the population that make them more susceptible to this specific variant. Environmental factors, such as exposure to certain infections or dietary habits, may also play a role. For example, certain strains of bacteria like Campylobacter jejuni, which are more prevalent in some regions, are known of the triggers but not the comment cause of GBS. The interaction between these genetic and environmental factors likely contributes to the higher incidence of AMAN in specific areas like China. Additionally, the healthcare infrastructure and diagnostic capabilities in different regions may influence the reporting and identification of GBS subtypes. In some cases, the prevalence of certain infections or environmental triggers may vary by region, leading to differences in the types of GBS seen. The severity of GBS can also vary depending on the subtype, with AMAN being particularly severe because it involves damage to the nerve axons themselves, rather than just the myelin sheath. This makes the recovery process more challenging and highlights the importance of understanding the regional variations in GBS to improve diagnosis and treatment. The higher prevalence of AMAN in China underscores the need for region-specific research and interventions to address the unique challenges posed by this variant of GBS.
Given that we don’t fully understand why GBS happens, how does a neurologist approach treatment when much about the disease remains unknown?
Despite the unknowns surrounding the exact cause of GBS, neurologists focus on managing the symptoms and halting the immune system’s attack on the nerves. The two main treatments are plasma exchange (plasmapheresis) and intravenous immunoglobulins (IVIG). Plasmapheresis involves removing the patient’s blood, filtering out the harmful antibodies, and returning the cleaned blood to the body. IVIG involves administering antibodies from healthy donors to modulate the immune response. Both treatments aim to reduce the immune system’s attack on the nerves. Early intervention is critical to prevent severe nerve damage and improve outcomes. Neurologists also monitor patients closely for complications, such as respiratory failure, and provide supportive care, including physiotherapy, to aid recovery. The approach to treatment is largely empirical, based on what has been shown to work in clinical trials and practice. While the exact mechanism of GBS may not be fully understood, the focus is on stopping the immune system’s attack and supporting the patient through the recovery process. This often involves a multidisciplinary approach, with neurologists, physiotherapists, and other healthcare professionals working together to provide comprehensive care. The goal is to stabilise the patient, prevent further damage, and support the body’s natural healing processes. Despite the uncertainties, the treatments available have been shown to be effective in most cases, and ongoing research continues to improve our understanding of GBS and its management. Recent studies have indicated that complement inhibitors, such as eculizumab, may offer a novel therapeutic approach in severe cases of GBS by targeting specific pathways involved in nerve damage.
Experts sometimes describe GBS symptoms as a “nervous breakdown,” with rapid muscle weakness and paralysis. How do doctors differentiate between GBS and similar neurological disorders in those critical initial moments?
GBS is characterised by rapid onset of symmetrical weakness, often starting in the legs and ascending to the arms and upper body. Unlike stroke, which typically affects one side of the body, GBS usually affects both sides. Doctors rely on a combination of clinical history, physical examination, and diagnostic tests to differentiate GBS from other neurological disorders. Nerve conduction studies and electromyography (EMG) can help assess nerve function and identify damage to the myelin sheath or axons. A lumbar puncture may also be performed to check for elevated protein levels in the cerebrospinal fluid, which is a common finding in GBS. These tests, along with the clinical presentation, help doctors confirm the diagnosis and rule out other conditions like stroke, multiple sclerosis, or spinal cord disorders. The rapid progression of symptoms, the pattern of weakness, and the absence of other neurological signs, such as sensory loss or cognitive changes, are key clues that point to GBS. Early diagnosis is crucial because prompt treatment can significantly improve outcomes and prevent complications like respiratory failure. The ability to differentiate GBS from other conditions is essential for providing the right treatment and ensuring the best possible outcome for the patient.
The myelin sheath is critical to nerve function and is severely impacted by GBS. Could you unpack what happens when myelin is damaged—why is this particular damage so devastating to nerve communication?
The myelin sheath acts as insulation for nerves, ensuring efficient transmission of electrical signals. In GBS, the immune system attacks this myelin, leading to demyelination. When the myelin is damaged, the nerve signals are disrupted or lost, resulting in muscle weakness, numbness, and impaired coordination. The brain’s commands cannot reach the muscles effectively, leading to paralysis in severe cases. Additionally, the speed of nerve signal transmission is slowed down, causing delays in muscle responses. The damage to the myelin sheath is particularly devastating because it affects the nerves’ ability to communicate with the muscles, leading to the characteristic symptoms of GBS. Over time, the body can repair some of the damage, but the recovery process can be slow and may not be complete in all cases. The myelin sheath is essential for the proper functioning of the nervous system, and its damage can have widespread effects on movement, sensation, and coordination. The loss of myelin not only disrupts nerve signals but also makes the nerves more vulnerable to further damage, complicating the recovery process. The importance of the myelin sheath in nerve function underscores why its damage in GBS is so debilitating and why treatments focus on halting the immune system’s attack to prevent further harm.
Given India’s public health challenges—limited healthcare access, delays in diagnosis—what unique issues do we face in managing GBS compared to developed countries?
In India, managing GBS presents several challenges due to limited healthcare access, delays in diagnosis, and the high cost of treatments like IVIG or plasmapheresis. Many patients, especially in rural areas, may not have access to specialised neurology care or advanced medical facilities. Delays in diagnosis can lead to more severe nerve damage and poorer outcomes. Additionally, the cost of treatments can be prohibitive for many families, limiting their ability to access life-saving therapies. Public health initiatives to improve awareness, early diagnosis, and access to affordable treatments are crucial to addressing these challenges and improving outcomes for GBS patients in India. The lack of infrastructure and resources in rural areas further complicates the management of GBS, highlighting the need for targeted interventions to bridge the gap in healthcare access. The disparity in healthcare resources between urban and rural areas means that many patients do not receive timely or adequate care, which can have a significant impact on their recovery and long-term outcomes. Addressing these challenges requires a concerted effort from policymakers, healthcare providers, and the community to ensure that all patients have access to the care they need.
GBS recovery can sometimes be partial, leaving lasting disability. Could you reflect on the challenges of rehabilitation in the Indian healthcare landscape, particularly for those in less privileged communities?
Rehabilitation for GBS requires long-term physiotherapy and support to regain muscle strength and function. However, in India, access to rehabilitation services can be limited, especially in rural or under-resourced areas. Many patients may not have access to physiotherapy centres or trained professionals, and the cost of ongoing care can be a barrier. For less privileged communities, the lack of awareness about the importance of rehabilitation and the financial burden of long-term care can hinder recovery. Additionally, social stigma and lack of support systems may further complicate the rehabilitation process. Addressing these challenges requires a multi-faceted approach, including improving access to rehabilitation services, increasing awareness, and providing financial support for patients and their families. The recovery process can be slow and arduous, and without adequate support, many patients may be left with lasting disabilities. The challenges of rehabilitation in India highlight the need for a more inclusive and accessible healthcare system that can provide the necessary support for patients with GBS and other neurological disorders. The lack of resources and infrastructure in many parts of the country means that many patients do not receive the care they need to fully recover, which can have a significant impact on their quality of life.
Given the sporadic and unpredictable nature of GBS, is there a role preventive healthcare measures can realistically play here? Or are we at the mercy of biology?
Preventive measures for GBS are limited due to its unpredictable nature. However, reducing the risk of infections through vaccination (e.g., flu or COVID-19 vaccines) and maintaining overall immune health may help. Public health initiatives to improve hygiene and infection control could also play a role in reducing the incidence of infections that trigger GBS. While we cannot completely prevent GBS, early recognition and treatment of infections, along with public health measures to reduce exposure to pathogens, may help lower the risk. Additionally, raising awareness about the early symptoms of GBS can lead to quicker diagnosis and treatment, improving outcomes for patients. The sporadic nature of GBS means that preventive measures are challenging, but focusing on overall health and infection control can help reduce the risk. The unpredictability of GBS underscores the importance of a strong and responsive healthcare system that can quickly identify and treat cases when they occur. While we may not be able to prevent GBS entirely, taking steps to reduce the risk of infections and improve overall health can help mitigate the impact of this condition.
Finally, stepping back a bit, how does a disease like GBS, sudden and severe yet relatively rare, influence public perception of neurological disorders in India? Does it shape policy, or is it overlooked because of its rarity?
GBS, though rare, highlights the importance of awareness and preparedness for neurological disorders. High-profile cases or outbreaks, like the Pune cluster, can draw attention to the need for better healthcare infrastructure and policy support. However, its rarity means it may not always receive the focus it deserves compared to more common conditions. Public perception of neurological disorders is often shaped by the visibility and impact of these conditions. While GBS can lead to severe disability, its sporadic nature means it may not always be prioritised in public health policies. However, every outbreak or cluster of cases serves as a reminder of the need for robust healthcare systems and policies to address rare but severe conditions like GBS. Increasing awareness and understanding of GBS can help shape policies that improve access to care and support for patients and their families. The rarity of GBS makes it a challenging condition to address, but it also underscores the importance of being prepared for unexpected health challenges. The impact of GBS on public perception and policy is a reminder that even rare conditions can have a significant impact on individuals and communities, and that a strong healthcare system must be prepared to address a wide range of health challenges.
Got a story that Healthcare Executive should dig into? Shoot it over to arunima.rajan@hosmac.com—no PR fluff, just solid leads.